Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Open-label Two-stage Safety and Tolerability Study With Subcutaneous Administration of Andes-1537 for Injection in Patients With Specific Types of Advanced Solid Tumors That Are Refractory To or No Available Standard Therapy

NCT03985072 is registered in ClinicalTrials.gov with Andes Biotechnologies as lead sponsor.

NCT NCT03985072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03985072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Open-label Two-stage Safety and Tolerability Study With Subcutaneous Administration of Andes-1537 for Injection in Patients With Specific Types of Advanced Solid Tumors That Are Refractory To or No Available Standard Therapy
Lead sponsor
Andes Biotechnologies
Phase
Phase 1
Overall status
Completed
Start date
April 26, 2019
Completion date
February 17, 2022
Enrollment
67 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, colorectal cancer, gall bladder cancer, gastric cancer, pancreatic cancer, tumor, solid